Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2016

Sarilumab ve Metotreksat Kombinasyonu Metotreksata Yetersiz Yanıtlı Aktif Romatoid Artrit Hastalarında Hasta Tarafından Bildirilen Sonuçları (PRO) İyileştirir: Bir Faz III Çalışmanın Sonuçları

Arthritis Res Ther 2016; 18:198. DOI.10.1186/s13075-016-9

Fan C,

Evidence is presented that treatment with sarilumab improves patient-reported outcomes (PROs). These improvements complement the clinical efficacy previously reported for sarilumab.Data were analysed from the 52-week Phase 3 MOBILITY randomised controlled trial in adult patients with active RA and previous inadequate response to MTX. Patients received subcutaneous placebo or sarilumab 150 mg or 200 mg every 2 weeks in combination with MTX, for 52 weeks.PROs assessed were: Patient Global Assessme...

Keywords:

Aktif Romatoid Artrit Hastalarında Tofasitinib ve Konvansiyonel DMARD Kombinasyonu: Randomize Kontrollü Faz 3 Çalışma

Arthritis Care Res 2016; Accepted article. DOI 10.1002/acr.23004

Further evidence is presented that treatment with tofacitinib improves patient-reported outcomes (PROs), in addition to improving underlying disease activity.Data were analysed from the Phase 3 ORAL Sync 12-month randomised controlled trial in adult patients with active RA and previous inadequate response to ≥1 conventional or biologic DMARD(s). Patients received (4:4:1:1) TOF 5mg or 10mg BID or Placebo advanced to 5 mg or10 mg BID plus conventional DMARD(s).PROs assessed at Month 3 were: Patien...